These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21881978)

  • 1. Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
    Xu M; Fan L; Miao KR; Liu P; Xu W; Li JY
    Med Oncol; 2012 Sep; 29(3):2102-10. PubMed ID: 21881978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.
    Lucas DM; Ruppert AS; Lozanski G; Dewald GW; Lozanski A; Claus R; Plass C; Flinn IW; Neuberg DS; Paietta EM; Bennett JM; Jelinek DF; Gribben JG; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS; Byrd JC; Grever MR
    Leuk Lymphoma; 2015; 56(11):3031-7. PubMed ID: 25721902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
    Jain N; Thompson P; Burger J; Ferrajoli A; Takahashi K; Estrov Z; Borthakur G; Bose P; Kadia T; Pemmaraju N; Sasaki K; Konopleva M; Jabbour E; Garg N; Wang X; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang S; Lopez W; Ayala A; Plunkett W; Gandhi V; Kantarjian H; O'Brien S; Keating M; Wierda WG
    Leukemia; 2021 Dec; 35(12):3421-3429. PubMed ID: 34007049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
    Schlette EJ; Admirand J; Wierda W; Abruzzo L; Lin KI; O'Brien S; Lerner S; Keating MJ; Tam C
    Leuk Lymphoma; 2009 Oct; 50(10):1597-605. PubMed ID: 19863337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
    J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
    Appleby N; O'Brien D; Quinn FM; Smyth L; Kelly J; Parker I; Scott K; Cahill MR; Crotty G; Enright H; Hennessy B; Hodgson A; Leahy M; O'Leary H; O'Dwyer M; Hayat A; Vandenberghe EA
    Leuk Lymphoma; 2018 Jun; 59(6):1338-1347. PubMed ID: 28925785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia.
    Xu W; Wang YH; Fan L; Fang C; Zhu DX; Wang DM; Qiao C; Wu YJ; Li JY
    Leuk Res; 2011 Aug; 35(8):1060-5. PubMed ID: 21208658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
    Grever MR; Lucas DM; Dewald GW; Neuberg DS; Reed JC; Kitada S; Flinn IW; Tallman MS; Appelbaum FR; Larson RA; Paietta E; Jelinek DF; Gribben JG; Byrd JC
    J Clin Oncol; 2007 Mar; 25(7):799-804. PubMed ID: 17283363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms and haplotypes in multidrug resistance 1 gene are not associated with chronic lymphocytic leukemia susceptibility and prognostic parameters of chronic lymphocytic leukemia in Chinese population.
    Dong HJ; Miao KR; Qiao C; Zhuang Y; Shen WY; Hong M; Fan L; Liu P; Xu W; Li JY
    Leuk Lymphoma; 2011 Jun; 52(6):1003-9. PubMed ID: 21463115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
    Thompson PA; Tam CS; O'Brien SM; Wierda WG; Stingo F; Plunkett W; Smith SC; Kantarjian HM; Freireich EJ; Keating MJ
    Blood; 2016 Jan; 127(3):303-9. PubMed ID: 26492934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.
    Wang DM; Liu L; Fan L; Zou ZJ; Zhang LN; Yang S; Li JY; Xu W
    Cancer Biol Ther; 2012 Dec; 13(14):1522-8. PubMed ID: 23052131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
    J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
    Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
    Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
    García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
    Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
    Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
    J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].
    Nikitin EA; Stadnik EA; Lorie IuIu; Biderman BV; Tsyba NN; Salogub GN; Kolosheĭnova TI; Kolosova LIu; Risinskaia NA; Zaritskiĭ IuA; Kovaleva LG; Sudarikov AB
    Ter Arkh; 2007; 79(7):66-70. PubMed ID: 17802794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
    Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
    Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of p53 gene deletion in Xinjiang patients with chronic lymphocytic leukemia by fluorescence in situ hybridization and its clinical significance].
    Maimaitili Y; Guzailinuer W; Wang X; Liu H; Li Y; Xiao M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Aug; 31(4):499-503. PubMed ID: 25119920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
    Gonzalez D; Martinez P; Wade R; Hockley S; Oscier D; Matutes E; Dearden CE; Richards SM; Catovsky D; Morgan GJ
    J Clin Oncol; 2011 Jun; 29(16):2223-9. PubMed ID: 21483000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.